I-C eye drops ease mild-to-moderate dry eye in early trial
A clinical trial in Spain found that iota-carrageenan eye drops significantly reduced symptoms of mild-to-moderate dry eye disease over four weeks. The treatment is derived from red seaweed and is considered safe for ocular use.
Why it matters
Dry eye disease is a widespread condition, and this natural, non-absorbed treatment offers a potential alternative to existing lubricant-based therapies.
Findings from a recent study published in Clinical Ophthalmology show that iota-carrageenan (I-C) eye drops eased dry eye disease (DED) symptoms and protected the ocular surface in adults with mild-to-moderate disease.
Some context: DED is one of the most common reasons patients see eyecare practitioners (as evidenced in the Tear Film Ocular Society’s DEWS II ), and its global prevalence runs anywhere from 5% to 50% depending on region and age group (see this epidemiology report for more on this).
The lubricant market has been dominated for decades by hyaluronic acid (HA) products. Innovation since then has mostly meant new combinations of existing compounds.
But real gaps remain , with tolerability issues, little ability to help damaged tissue heal, and a therapeutic effect that can take weeks or months to kick in.
The pitch: I-C is a natural polysaccharide extracted from red seaweed.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in